MedTrace Logo

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

NCT00002015 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2005-06-24

No results posted yet for this study

Summary

To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving treatment for life- or sight-threatening cytomegalovirus infections.

Conditions

  • Cytomegalovirus Retinitis
  • HIV Infections

Interventions

DRUG

Ganciclovir

Sponsors & Collaborators

  • Roche Global Development

    lead OTHER

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
3 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002015 on ClinicalTrials.gov